Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana

Table 3 Implications of Drug Resistance Associated Mutations Detected

HIV-1 Drug status	Mutations	Drug resistance	Useful drug options
NRTI
Art after prophylaxis	M184 V	3TC,FTC,DDI,ABC	AZT,TDF D4T
	M184 V,M41 L,T215Y	ABC,AZT,D4T,DDI, TDF,3TC,FTC	NONE
	M184 V,M41 L,L74 V, T215Y	ABC,AZT,DDI,	3TC,FTC
Art no prophylaxis	M184 V,D67G,M41 LM, K70R,K219E,T215I	3TC,AZT,FTC,ABC, D4T,DDI,TDF	NONE
	M184 V	3TC,FTC,DDI,ABC	AZT,TDF,D4T,
	M184 V,Y115F,T215S	ABC,TDF	3TC,FTC,DDI
Drug-naive	M184 V	3TC,ABC,DDI,FTC	AZT,D4T,TDF
Drug-naive	L210 W	AZT,ABC,DDI,FTC, TDF	3TC
NNRTI
Art after prophylaxis	K103 N,Y181C	NVP,EFV,ETR,RPV	NONE
	A98G,K103 N,M230 LM	NVP,EFV,ETR,RPV	NONE
	K103 N,M230 L,L100IL, A98G	NVP,EFV,ETR,RPV	NONE
Art no prophylaxis	A98G	NVP	EFV
Drug-naive	K103 N	NVP,EFV	NONE
	V106A	NVP,EFV	NONE
	E138A	NVP,EFV,ETR,RPV	NONE
	A98G	NVP	EFV

NRTI Nucleoside Reverse Transcriptase Inhibitors, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors

ISSN: 1743-422X